# Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

> **NCT00376688** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Recurrent Breast Carcinoma
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00376688
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-11
- **Primary completion:** 2008-06-12
- **Final completion:** 2019-12-16
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376688, "Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00376688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*